Business
Stella Diagnostics to Present at “Next Big Thing” Session at Society of American Gastroenterologists and Endoscopic Surgeons Annual Meeting
Stella Diagnostics to Present at “Next Big Thing” Session at Society of American Gastroenterologists and Endoscopic Surgeons Annual Meeting.
About this update from Stella Diagnostics Inc.
[{"type":"text","content":"\n Stella Diagnostics Designated as a Semi-Finalist for SAGES Shark Tank 2022Stella Diagnostics and Collaborators to Give a Clinical Science Data Presentation at Major Medical Conference in Denver DENVER, March 02, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and cancerous esophageal diseases, today announced its abstract, “Multi-Institutional Study Assessing STLA101 Assay Performance for the Detection of Cancerous Progression in Barrett's Esophagus”, has been selected for the Next Big Thing session at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2022 Annual Meeting. The congress will be held March 16-19, 2022, at the Colorado Convention Center in Denver. The dataset will be presented by Sumeet K. Mittal, MD, Clinical Advisor to Stella Diagnostics, board certified surgeon, and Surgical Director of the Esophageal and Foregut Program at Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center. The abstract will be co-presented by Dr. Christopher Hartley of the Mayo Clinic, and principal investigator of Stella Diagnostics’ Collaborative Research Agreement with the Mayo Clinic to assess the performance of the Company's STLA101 panel that detects and quantifies hallmarks of cancer development in tissue of patients diagnosed with Barrett's esophagus (a precancerous condition with high incidence). Hosted By: Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Program Number: ETP433/ NEXT BIG THING SESSION Session Date: Wednesday, March 16, 2022 - Saturday, March 19, 2022 Session Time: 8:00 AM - 4:00 PM Dr. Joe Abdo, CEO of Stella Diagnostics, said, “It is an honor to be selected for participation in The Next Big Thing session for SAGES, and we are very grateful to be designated as an organization that can create a paradigm shift for precancer screening. SAGES is one of the world’s premier professional organizations for gastrointestinal observation, early cancer detection screening and endoscopic surgery, which is our primary user market. This is a tremendous opportunity to provide more information about the clinical advantages of our diagnostic assays to the thousands of gastroenterologists who are membe...